Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Dr. Reddy's Laboratories Ltd. Share Price
Day's Range
Day's Range
Low
₹1,201.20
High
₹1,229.90
Price Summary
| Previous Close | ₹1,211.20 |
|---|---|
| Day's Range | ₹1,201.20 - ₹1,229.90 |
| Open | ₹1,227.50 |
| 52 Week Range | ₹1,148.40 - ₹1,414.90 |
| Volume | 20,75,149 |
| Market Cap | ₹0.10 |
| Previous Close | ₹1,210.85 |
|---|---|
| Day's Range | ₹1,203.00 - ₹1,233.35 |
| Open | ₹1,225.00 |
| 52 Week Range | ₹1,149.00 - ₹1,414.40 |
| Volume | 87,318 |
| Market Cap | ₹0.10 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 25,119.32 |
|---|---|
| Market Cap (₹ in Mn) | 0.10 |
| Dividend Yield(%) | 0.66 |
| Price/Earning (TTM) | 24.09 |
| TTM EPS (₹) | 50.27 |
| P/E Ratio | 24.97 |
| Book Value(₹) | 2.68 |
| PAT Margin (%) | 12.34 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 13.75 |
| Trade Value ( ₹ in Lacs) | 1,057.88 |
|---|---|
| Market Cap (₹ in Mn) | 0.10 |
| Dividend Yield(%) | 0.66 |
| Price/Earning (TTM) | 24.09 |
| TTM EPS (₹) | 50.27 |
| P/E Ratio | 24.97 |
| Book Value(₹) | 2.68 |
| PAT Margin (%) | 12.34 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 13.75 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 326439.0 | 85284.0 |
| Expenses | N/A | N/A |
| PBT | 76795.0 | 20052.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 57252.0 | 15867.0 |
About Dr. Reddy's Laboratories Ltd.
| Founded | 1984 |
|---|---|
| Managing Director | GV Prasad |
| NSE Symbol | DRREDDY |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,63,815.44 | 1,933.10 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,92,678.42 | 7,258.05 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,61,323.40 | 4,766.60 | 3,466.00 - 3,466.00 |
| Apollo Hospitals Enterprise Ltd. | 1,26,836.04 | 8,815.40 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,14,584.78 | 1,418.40 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,13,989.75 | 1,142.75 | 835.50 - 835.50 |
| Lupin Ltd. | 1,11,661.33 | 2,441.50 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,06,057.61 | 1,090.45 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,02,895.88 | 2,491.45 | 1,909.70 - 1,909.70 |
| Dr. Reddy's Laboratories Ltd. | 1,01,066.72 | 1,210.85 | 1,148.40 - 1,148.40 |
No Records Found
Latest News
Dr. Reddy’s Laboratories informs about audio recording of conference call
Dr. Reddy’s Laboratories informs about analyst meet
Dr. Reddy’s Laboratories has informed that certain batches of semaglutide were found to be out of specification due to an issue associated with the active pharmaceutical ingredient (API) used in the product. The company is investigating the root cause and taking appropriate measures to ensure product quality. Until the issue is resolved, commercial supplies of the product will be delayed for a certain period of time. There is no impact on patient safety or on the product's existing global regulatory filings. The company remain committed to ensuring reliable global supplies of this important metabolic therapy. The management of the Company will host a conference call on Thursday, July 9, 2026 at 16:30 – 17:00 IST 07:00 – 07:30 ET to discuss the topic and answer any questions from the participants. The Pre-register link to join is enclosed. The transcript of the conference call will be available on the Company’s website: www.drreddys.com.
The above information is a part of company’s filings submitted to BSE.
Dr Reddys Laboratories informs about AGM
Dr Reddys Laboratories informs about press release
Dr. Reddy’s Laboratories informs about press release
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Dr. Reddy's Laboratories Ltd. is ₹1,211.20 as of 2026-07-17.
The market capitalisation of Dr. Reddy's Laboratories Ltd. is ₹101,066.72 as of 2026-07-17.
The 1-year return of Dr. Reddy's Laboratories Ltd. is -51.90% as of 2026-07-17.
The P/E ratio of Dr. Reddy's Laboratories Ltd. is 24.97 as of 2026-07-18.
The 52-week high and low of Dr. Reddy's Laboratories Ltd. are ₹1,414.90 and ₹1,148.40, respectively, as of 2026-07-17.
People Also Ask
Dr. Reddy's manufactures innovative immunotherapy drug (Zytorvi – PD-1 monoclonal antibody), generic pharmaceuticals (Abiraterone, Dasatinib, Imatinib for oncology; Pregabalin, Teriflunomide for specialty therapies), antibiotics (Daptomycin, Ciprofloxacin), pain management drugs. Global operations, multi-therapeutic portfolio spanning oncology, immunology, cardiology, neurology segments.
Dr. Reddy's collaborates with hospital networks for clinical trials, healthcare providers for treatment protocols, research institutions for drug development, global pharmaceutical partners for commercialisation, patient assistance programs through healthcare partnerships, and supply chain integration with dispensary networks ensuring drug accessibility nationwide.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
